Johnson & Johnson Stock Holds Firm Above $270 Amid Q2 Earnings Beat

Johnson & Johnson stock has held steady above $270 after a strong Q2 earnings beat and an increase in full-year guidance. The shares closed at $270.00 on August 26, 2026, following a session that left the price close to recent highs.

The company's resilient healthcare demand, continued growth in pharmaceuticals and medical technology, and shareholder-friendly capital return policy have contributed to its positioning above $270. This mix of factors has made Johnson & Johnson a key defensive holding, offering measured growth through 2026.

In the second quarter of 2026, Johnson & Johnson delivered worldwide sales of $25.31 billion, exceeding analyst expectations and marking a clear step up from the prior-year period. Adjusted diluted earnings per share came in at $2.90, also above market consensus, indicating that the company successfully managed costs and mix to translate revenue growth into profit expansion.